Rheumatoid Arthritis eJournal Club
   

Managing Rheumatoid Arthritis Patients with an Inadequate
Response to TNF Inhibitors

Print this Content
Release Date:  November 14, 2008 Renewal Date:  November 14, 2009 Expiration Date:  May 14, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion 1 hour
Description / Overview

The purpose of this activity is to discuss treatment options for a patient with rheumatoid arthritis (RA) who has had a lack of response to one or more biologic disease-modifying antirheumatic drugs (DMARDs).

Objectives At the conclusion of this activity, the participant will be able to:
  1. Discuss the response to tumor necrosis factor (TNF) inhibitors reported from pivotal trials.
  2. Identify reported adherence to TNF inhibitor regimens and reasons for discontinuing these regimens.
  3. Assess treatment options beyond TNF inhibition for a patient with RA when it is determined that therapy with a TNF inhibitor is no longer beneficial.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.

Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty Sandeep K. Agarwal, MD, PhD
Assistant Professor
Division of Rheumatology and Clinical Immunogenetics
Department of Internal Medicine
The University of Texas Health Science Center Houston–Medical School
Houston, Texas
Faculty Disclosure

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:

Leonard Calabrese, DO
  Consulting: Abbott Laboratories;
Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.

The following faculty has indicated he has no relationship which, in the context of his presentation, could be preceived as a potential conflict of interest:

Sandeep K. Agarwal, MD, PhD

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

Bristol – Myers Squibb Company, Genentech/Biogen Idec

Wyeth Pharmaceuticals

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME.

CME Disclaimer

 

 
Bookmark this Chapter
Copyright © 2000-2010 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 9500 Euclid Avenue, KK31, Cleveland, OH 44195
Copyright © 2000-2010 The Cleveland Clinic Foundation. All Rights Reserved.
Center for Continuing Education | 9500 Euclid Avenue, KK31, Cleveland, OH 44195